Hong Jae Chon, Director of Cancer Center, CHA Bundang Medical Center, shared a post on X:
“In real-world HCC practice, do patients ineligible for the HIMALAYA trial still benefit from durvalumab plus tremelimumab?
Trial-eligible patients had median OS of 19.4 vs. 15.4 months, but ineligible patients with preserved liver function (ALBI grade 1) achieved comparable survival.
Multicenter retrospective study by Matono et al. has recently been published in Journal of Gastroenterology and Hepatology.
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial.”
Title: Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Authors: Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Yoshiko Nakamura, Osamu Yoshida, Kazuya Kariyama, Kazuhiro Nouso, Joji Tani, Asahiro Morishita, Masanori Atsukawa, Norio Itokawa, Tomomi Okubo, Taeang Arai, Koichi Takaguchi, Akemi Tsutsui, Takuya Nagano, Ei Itobayashi, Takashi Nishimura, Shinya Fukunishi, Hirayuki Enomoto, Kunihiko Tsuji, Kazunari Tanaka, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Yuichi Koshiyama, Chikara Ogawa, Takeshi Hatanaka, Yuki Kanayama, Satoru Kakizaki, Kazuhito Kawata, Hidenao Noritake, Atsushi Naganuma, Hisashi Kosaka, Kosuke Matsui, Masaki Kaibori, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Jumpei Okamura, Shohei Komatsu, Takanori Matsuura, Shinichiro Nakamura, Yoshihide Ueda, Soo Ki Kim, Hideko Ohama, Fujimasa Tada, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada.
Other articles about GI Oncology on OncoDaily.